This article is more than 5 years old. Information may no longer be current.

Nicox quarterly revenue increases

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nicox reported net revenue of 3.3 million euros in the fourth quarter of 2018 compared with net revenue of 2.3 million euros in 2017’s fourth quarter.

The total includes an upfront payment from Ocumension for NCX 470 for the Chinese market and royalties on sales of Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) by the company’s global partner Bausch + Lomb, according to a press release.

In the fourth quarter, Vyzulta prescriptions in the U.S. rose by 47% compared with the third quarter of the year.

The company’s year-end net revenue totaled 4 million euros.